Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Syndecan 4-c-ros oncogene 1 fusion as a mechanism of acquired resistance in epidermal growth factor receptor mutant lung adenocarcinoma.

Chinese medical journal - 20 Dec 2019

Zhu You-Cai, Xu Chun-Wei, Zhang Qu-Xia, Wang Wen-Xian, Lei Lei, Zhuang Wu

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Drug Resistance, Neoplasm
Share to ErbB Receptors
Share to Gene Rearrangement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 31809319
DOI: 10.1097/CM9.0000000000000555
PMCID: PMC6964938

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Syndecan 4-c-ros oncogene 1 fusion as a mechanism of acquired resistance in epidermal growth factor receptor mutant lung adenocarcinoma.PMID 31809319Read ↗

ROS-1 TKI for the treatment of concurrent sarcomatoid transformation and acquired ROS-1 F2004C mutation in a lung adenocarcinoma patient.Semantic proximity Read ↗

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review.Semantic proximity Read ↗

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapySemantic proximity Read ↗

[Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].Semantic proximity Read ↗

EZR-ROS1 rearrangement as a novel mechanism of acquired resistance to EGFR-TKIs in NSCLC: a case report and literature review.Semantic proximity Read ↗

Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion.Semantic proximity Read ↗

Mouse Model for ROS1-Rearranged Lung CancerSemantic proximity Read ↗

[Clinicopathological analysis of 4 cases of lung cancer with concomitant EGFR mutation and ROS1 fusion].Semantic proximity Read ↗

Acquired resistance to crizotinib from a mutation in CD74-ROS1.Semantic proximity Read ↗

Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma.Semantic proximity Read ↗

Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.Semantic proximity Read ↗

Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.